Distinguishing undifferentiated embryonal sarcoma of the liver from biliary tract rhabdomyosarcoma

A children's oncology group study

Kathleen Nicol, Van Savell, Julie Moore, Lisa Teot, Sheri L. Spunt, Stephen Qualman, Richard J. Andrassy, Carola A.S. Arndt, K. Scott Baker, Frederic G. Barr, W. Archie Bleyer, Philip Breitfeld, John C. Breneman, Julia Bridge, Kenneth Brown, Sarah S. Donaldson, Holcome E. Grier, Douglas Hawkins, Peter J. Houghton, Michael Link & 18 others Thom L. Lobe, Harold M. Maurer, William H. Meyer, Jeff Michalski, Charles N. Paidas, Alberto S. Pappo, David M. Parham, R. Beverly Raney, Leslie Robison, Eric Sandler, Stephen Skapek, Lynn Smith, Paul H B Sorenson, David Walterhouse, Moody Wharam, Eugene S. Wiener, Suzanne Wolden, Richard Womer

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Morphologically, the distinction between undifferentiated embryonal sarcoma of the liver (UESL) and biliary tract rhabdomyosarcoma (RMS) can be uncertain because of some shared pathologic similarities. Patients with UESL have been consistently but erroneously enrolled in Children's Oncology Group (COG) treatment protocols because UESL was equated with RMS, despite the differing primary treatment modalities of these entities. Review of COG pathology files yielded 20 cases of UESL that were compared to 25 cases of biliary tract RMS. Clinicopathologic features including immunohistochemical staining were examined. In the UESL cases, the male:female ratio was 1:1 and the median age was 10.5 years. Histologically, hyaline globules and diffuse anaplasia were consistently present. The cases of RMS had a male:female ratio of 1.8:1 with a median age of 3.4 years and routinely lacked diffuse anaplasia and hyaline globules. Polyclonal desmin and muscle-specific actin were variably immunoreactive in UESL and RMS; however, myogenin and myogenic regulatory protein D1 (MyoD1) were uniformly negative in UESL and routinely positive in the majority of biliary tract RMS. Myogenin, in particular, was highly significant (P = 0.0003) in distinguishing RMS from UESL. With a median follow-up of 8 months, 11 of 18 patients with UESL were still alive. The estimated 5-year survival for biliary tract RMS was 66%. Establishing the correct diagnosis of these distinct clinical and pathologic entities is important, as surgery alone may be curative in UESL, whereas initial chemotherapy is often recommended for the treatment of biliary tract RMS.

Original languageEnglish (US)
Pages (from-to)89-97
Number of pages9
JournalPediatric and Developmental Pathology
Volume10
Issue number2
DOIs
StatePublished - Mar 2007

Fingerprint

Rhabdomyosarcoma
Biliary Tract
Sarcoma
Liver
Anaplasia
Myogenin
Hyalin
Embryonal Rhabdomyosarcoma
Desmin
Clinical Protocols
Actins
Pathology
Staining and Labeling
Drug Therapy
Muscles
Survival

Keywords

  • Biliary tract
  • Child
  • Liver
  • Pediatric
  • Rhabdomyosarcoma
  • Undifferentiated embryonal sarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pathology and Forensic Medicine

Cite this

Distinguishing undifferentiated embryonal sarcoma of the liver from biliary tract rhabdomyosarcoma : A children's oncology group study. / Nicol, Kathleen; Savell, Van; Moore, Julie; Teot, Lisa; Spunt, Sheri L.; Qualman, Stephen; Andrassy, Richard J.; Arndt, Carola A.S.; Baker, K. Scott; Barr, Frederic G.; Bleyer, W. Archie; Breitfeld, Philip; Breneman, John C.; Bridge, Julia; Brown, Kenneth; Donaldson, Sarah S.; Grier, Holcome E.; Hawkins, Douglas; Houghton, Peter J.; Link, Michael; Lobe, Thom L.; Maurer, Harold M.; Meyer, William H.; Michalski, Jeff; Paidas, Charles N.; Pappo, Alberto S.; Parham, David M.; Raney, R. Beverly; Robison, Leslie; Sandler, Eric; Skapek, Stephen; Smith, Lynn; Sorenson, Paul H B; Walterhouse, David; Wharam, Moody; Wiener, Eugene S.; Wolden, Suzanne; Womer, Richard.

In: Pediatric and Developmental Pathology, Vol. 10, No. 2, 03.2007, p. 89-97.

Research output: Contribution to journalArticle

Nicol, K, Savell, V, Moore, J, Teot, L, Spunt, SL, Qualman, S, Andrassy, RJ, Arndt, CAS, Baker, KS, Barr, FG, Bleyer, WA, Breitfeld, P, Breneman, JC, Bridge, J, Brown, K, Donaldson, SS, Grier, HE, Hawkins, D, Houghton, PJ, Link, M, Lobe, TL, Maurer, HM, Meyer, WH, Michalski, J, Paidas, CN, Pappo, AS, Parham, DM, Raney, RB, Robison, L, Sandler, E, Skapek, S, Smith, L, Sorenson, PHB, Walterhouse, D, Wharam, M, Wiener, ES, Wolden, S & Womer, R 2007, 'Distinguishing undifferentiated embryonal sarcoma of the liver from biliary tract rhabdomyosarcoma: A children's oncology group study', Pediatric and Developmental Pathology, vol. 10, no. 2, pp. 89-97. https://doi.org/10.2350/06-03-0068.1
Nicol, Kathleen ; Savell, Van ; Moore, Julie ; Teot, Lisa ; Spunt, Sheri L. ; Qualman, Stephen ; Andrassy, Richard J. ; Arndt, Carola A.S. ; Baker, K. Scott ; Barr, Frederic G. ; Bleyer, W. Archie ; Breitfeld, Philip ; Breneman, John C. ; Bridge, Julia ; Brown, Kenneth ; Donaldson, Sarah S. ; Grier, Holcome E. ; Hawkins, Douglas ; Houghton, Peter J. ; Link, Michael ; Lobe, Thom L. ; Maurer, Harold M. ; Meyer, William H. ; Michalski, Jeff ; Paidas, Charles N. ; Pappo, Alberto S. ; Parham, David M. ; Raney, R. Beverly ; Robison, Leslie ; Sandler, Eric ; Skapek, Stephen ; Smith, Lynn ; Sorenson, Paul H B ; Walterhouse, David ; Wharam, Moody ; Wiener, Eugene S. ; Wolden, Suzanne ; Womer, Richard. / Distinguishing undifferentiated embryonal sarcoma of the liver from biliary tract rhabdomyosarcoma : A children's oncology group study. In: Pediatric and Developmental Pathology. 2007 ; Vol. 10, No. 2. pp. 89-97.
@article{0d750ba8b9994bb4b89c020cb0e96f54,
title = "Distinguishing undifferentiated embryonal sarcoma of the liver from biliary tract rhabdomyosarcoma: A children's oncology group study",
abstract = "Morphologically, the distinction between undifferentiated embryonal sarcoma of the liver (UESL) and biliary tract rhabdomyosarcoma (RMS) can be uncertain because of some shared pathologic similarities. Patients with UESL have been consistently but erroneously enrolled in Children's Oncology Group (COG) treatment protocols because UESL was equated with RMS, despite the differing primary treatment modalities of these entities. Review of COG pathology files yielded 20 cases of UESL that were compared to 25 cases of biliary tract RMS. Clinicopathologic features including immunohistochemical staining were examined. In the UESL cases, the male:female ratio was 1:1 and the median age was 10.5 years. Histologically, hyaline globules and diffuse anaplasia were consistently present. The cases of RMS had a male:female ratio of 1.8:1 with a median age of 3.4 years and routinely lacked diffuse anaplasia and hyaline globules. Polyclonal desmin and muscle-specific actin were variably immunoreactive in UESL and RMS; however, myogenin and myogenic regulatory protein D1 (MyoD1) were uniformly negative in UESL and routinely positive in the majority of biliary tract RMS. Myogenin, in particular, was highly significant (P = 0.0003) in distinguishing RMS from UESL. With a median follow-up of 8 months, 11 of 18 patients with UESL were still alive. The estimated 5-year survival for biliary tract RMS was 66{\%}. Establishing the correct diagnosis of these distinct clinical and pathologic entities is important, as surgery alone may be curative in UESL, whereas initial chemotherapy is often recommended for the treatment of biliary tract RMS.",
keywords = "Biliary tract, Child, Liver, Pediatric, Rhabdomyosarcoma, Undifferentiated embryonal sarcoma",
author = "Kathleen Nicol and Van Savell and Julie Moore and Lisa Teot and Spunt, {Sheri L.} and Stephen Qualman and Andrassy, {Richard J.} and Arndt, {Carola A.S.} and Baker, {K. Scott} and Barr, {Frederic G.} and Bleyer, {W. Archie} and Philip Breitfeld and Breneman, {John C.} and Julia Bridge and Kenneth Brown and Donaldson, {Sarah S.} and Grier, {Holcome E.} and Douglas Hawkins and Houghton, {Peter J.} and Michael Link and Lobe, {Thom L.} and Maurer, {Harold M.} and Meyer, {William H.} and Jeff Michalski and Paidas, {Charles N.} and Pappo, {Alberto S.} and Parham, {David M.} and Raney, {R. Beverly} and Leslie Robison and Eric Sandler and Stephen Skapek and Lynn Smith and Sorenson, {Paul H B} and David Walterhouse and Moody Wharam and Wiener, {Eugene S.} and Suzanne Wolden and Richard Womer",
year = "2007",
month = "3",
doi = "10.2350/06-03-0068.1",
language = "English (US)",
volume = "10",
pages = "89--97",
journal = "Pediatric and Developmental Pathology",
issn = "1093-5266",
publisher = "Society for Pediatric Pathology",
number = "2",

}

TY - JOUR

T1 - Distinguishing undifferentiated embryonal sarcoma of the liver from biliary tract rhabdomyosarcoma

T2 - A children's oncology group study

AU - Nicol, Kathleen

AU - Savell, Van

AU - Moore, Julie

AU - Teot, Lisa

AU - Spunt, Sheri L.

AU - Qualman, Stephen

AU - Andrassy, Richard J.

AU - Arndt, Carola A.S.

AU - Baker, K. Scott

AU - Barr, Frederic G.

AU - Bleyer, W. Archie

AU - Breitfeld, Philip

AU - Breneman, John C.

AU - Bridge, Julia

AU - Brown, Kenneth

AU - Donaldson, Sarah S.

AU - Grier, Holcome E.

AU - Hawkins, Douglas

AU - Houghton, Peter J.

AU - Link, Michael

AU - Lobe, Thom L.

AU - Maurer, Harold M.

AU - Meyer, William H.

AU - Michalski, Jeff

AU - Paidas, Charles N.

AU - Pappo, Alberto S.

AU - Parham, David M.

AU - Raney, R. Beverly

AU - Robison, Leslie

AU - Sandler, Eric

AU - Skapek, Stephen

AU - Smith, Lynn

AU - Sorenson, Paul H B

AU - Walterhouse, David

AU - Wharam, Moody

AU - Wiener, Eugene S.

AU - Wolden, Suzanne

AU - Womer, Richard

PY - 2007/3

Y1 - 2007/3

N2 - Morphologically, the distinction between undifferentiated embryonal sarcoma of the liver (UESL) and biliary tract rhabdomyosarcoma (RMS) can be uncertain because of some shared pathologic similarities. Patients with UESL have been consistently but erroneously enrolled in Children's Oncology Group (COG) treatment protocols because UESL was equated with RMS, despite the differing primary treatment modalities of these entities. Review of COG pathology files yielded 20 cases of UESL that were compared to 25 cases of biliary tract RMS. Clinicopathologic features including immunohistochemical staining were examined. In the UESL cases, the male:female ratio was 1:1 and the median age was 10.5 years. Histologically, hyaline globules and diffuse anaplasia were consistently present. The cases of RMS had a male:female ratio of 1.8:1 with a median age of 3.4 years and routinely lacked diffuse anaplasia and hyaline globules. Polyclonal desmin and muscle-specific actin were variably immunoreactive in UESL and RMS; however, myogenin and myogenic regulatory protein D1 (MyoD1) were uniformly negative in UESL and routinely positive in the majority of biliary tract RMS. Myogenin, in particular, was highly significant (P = 0.0003) in distinguishing RMS from UESL. With a median follow-up of 8 months, 11 of 18 patients with UESL were still alive. The estimated 5-year survival for biliary tract RMS was 66%. Establishing the correct diagnosis of these distinct clinical and pathologic entities is important, as surgery alone may be curative in UESL, whereas initial chemotherapy is often recommended for the treatment of biliary tract RMS.

AB - Morphologically, the distinction between undifferentiated embryonal sarcoma of the liver (UESL) and biliary tract rhabdomyosarcoma (RMS) can be uncertain because of some shared pathologic similarities. Patients with UESL have been consistently but erroneously enrolled in Children's Oncology Group (COG) treatment protocols because UESL was equated with RMS, despite the differing primary treatment modalities of these entities. Review of COG pathology files yielded 20 cases of UESL that were compared to 25 cases of biliary tract RMS. Clinicopathologic features including immunohistochemical staining were examined. In the UESL cases, the male:female ratio was 1:1 and the median age was 10.5 years. Histologically, hyaline globules and diffuse anaplasia were consistently present. The cases of RMS had a male:female ratio of 1.8:1 with a median age of 3.4 years and routinely lacked diffuse anaplasia and hyaline globules. Polyclonal desmin and muscle-specific actin were variably immunoreactive in UESL and RMS; however, myogenin and myogenic regulatory protein D1 (MyoD1) were uniformly negative in UESL and routinely positive in the majority of biliary tract RMS. Myogenin, in particular, was highly significant (P = 0.0003) in distinguishing RMS from UESL. With a median follow-up of 8 months, 11 of 18 patients with UESL were still alive. The estimated 5-year survival for biliary tract RMS was 66%. Establishing the correct diagnosis of these distinct clinical and pathologic entities is important, as surgery alone may be curative in UESL, whereas initial chemotherapy is often recommended for the treatment of biliary tract RMS.

KW - Biliary tract

KW - Child

KW - Liver

KW - Pediatric

KW - Rhabdomyosarcoma

KW - Undifferentiated embryonal sarcoma

UR - http://www.scopus.com/inward/record.url?scp=34147192773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147192773&partnerID=8YFLogxK

U2 - 10.2350/06-03-0068.1

DO - 10.2350/06-03-0068.1

M3 - Article

VL - 10

SP - 89

EP - 97

JO - Pediatric and Developmental Pathology

JF - Pediatric and Developmental Pathology

SN - 1093-5266

IS - 2

ER -